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Small fiber neuropathy (SFN) is being recognized with increasing frequency in 
neuromuscular practice due to improved diagnostic techniques. Although there are some 
common etiologies, up to one-third of cases are considered idiopathic. In recent years, several 
disorders have unexpectedly been reported in association with SFN, on clinical grounds and 
complementary investigations, including quantitative sensory testing, intraepidermal nerve 
fiber density and confocal corneal microscopy. Knowledge of these disorders is important in 
clinical practice as increased awareness enables prompt diagnosis of SFN in these settings 
and early optimal therapeutic management of affected patients. Furthermore, these new 
developments may lead to a better understanding of the pathophysiologic mechanisms 
underlying SFN in these different disorders as well as, in some cases, an expanded spectrum 
of affected organs and systems. This article reviews these reported associations, their possible 













Small fiber neuropathy (SFN) is a sensory peripheral nerve disorder with structural and 
functional abnormalities involving the small myelinated (Aδ) and unmyelinated (C) fibers 
and characterized pathologically by their degeneration (1). Aδ fibers transmit temperature 
and pain sensation after mechanical or thermal stimulation, but C fibers in addition to pain 
and temperature, are also involved in autonomic function (2, 3). SFN may present with or 
without autonomic dysfunction in association with pain and sensory loss. The incidence and 
prevalence of SFN is not well established. Due to lack of awareness together with a paucity 
of readily available diagnostic methods, SFN is probably under-recognized. In a cross-
sectional Dutch study, the overall minimum incidence has been reported as approaching 
12/100,000 per year and the overall minimum prevalence, about 53/100,000 (4). In terms of 
morbidity and disease burden, peripheral neuropathy is reported to be the leading cause of 
outpatient neurology appointments in the United States and accounts for more than $10 
billion in healthcare cost each year (5). Also, chronic neuropathic pain is reported in almost 
7% of adults (6). 
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The precise pathophysiologic mechanisms underlying SFN are often unknown and depend on 
the underlying etiology, including oxidative stress, ischemia, direct neurotoxic effect, 
hypoxia, and inflammatory mediators (7-9). The cause of SFN is not always identifiable. It 
may be as a result of diverse disorders, including metabolic, inflammatory, toxic, infectious, 
and genetic diseases. Diabetes (10) and impaired glucose tolerance are probably the most 
common (8,9). Impaired glucose tolerance may contribute to 15% of cases (11). Other 
possible reported etiologies include connective tissue disease, HIV and hepatitis C infections, 
thyroid dysfunction, vitamin B12 deficiency, multiple myeloma and monoclonal 
gammopathy, amyloidosis, alcohol or drugs, and genetic. Recently, new hereditary forms of 
SFN have been described with pathogenic mutations in sodium channels [Nav1.7, Nav1.8, 
and Nav1.9] which lead to hyperexcitability of dorsal root ganglia and sensory axons. These 
gain-of-function mutations result in degeneration of small fibers (12). In a recent study on 
921 patients with pure SFN, over 50% of cases were of undetermined cause (13). 
 
The diagnosis of SFN is now possible via different modalities. Quantitative sensory testing 
(QST) is a psychophysical investigation, using automated systems to deliver sensory stimuli 
in a quantifiable and reproducible manner. QST is highly patient-dependent and cannot be 
used to distinguish central from peripheral nervous system lesions (14). Skin biopsy with 
intraepidermal nerve C fiber density (IENFD) evaluation was developed and has been utilized 
for identification of SFN since the 1990s, greatly facilitating diagnosis. Counting rules have 
been established (15) and normative values derived, making IENFD measurement highly 
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reproducible (16). Confocal corneal microscopy (CCM) is a novel, non-invasive method to 
detect SFN, exploring the cornea, which receives the densest small fiber innervations of the 
body. The method correlates well with IENFD and has in recent years been found to be 
helpful in identifying SFN in a number of different clinical settings (17). 
 
Awareness of causes of SFN is important, as some are potentially treatable or curable. 
Conversely, several conditions have unexpectedly been reported recently to be accompanied 
by SFN. These conditions include a heterogeneous group of neurological and non-
neurological disorders in which small fiber involvement is unpredictable. A list of these 
disorders, both neurological and non-neurological, is provided in Table 1.  
 
Knowledge of these associations has become important for prompt recognition, as well as for 
early, adequate multidisciplinary management while in addition, potentially offering new 
insights in the pathophysiology of SFN. The aim of this review is to describe these newly-



























A search was performed using the PubMed database between January 1990 to December 
2019, for “small fiber/fibre neuropathy/pathology”. We included “small fiber/fibre 
pathology” (SFP) as the concept used to designate findings of small fiber damage in 
association with diseases not characterized by the clinical features of small fiber neuropathy, 
identified in disorders of different pathophysiology (18), as well as the presence of SFP as the 
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cause of painful disorders not previously known to have a neuropathic basis (19). Only 
English language publications were selected, and Abstracts were excluded. All case reports 
and original articles that were related to the combination of SFN and other neurologic/non-
neurologic conditions, except for commonly reported causes, were extracted and evaluated. 
Publications that were solely expert editorials or commentaries were excluded. Reports 
related to well-known causes of neuropathies such as glucose metabolism disorders, 
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Fibromyalgia (FM) (20) is a chronic widespread pain disorder with additional, non-specific 
symptoms such as fatigue, headache, cognitive dysfunction, mood disorder and sleep 
disturbances. This syndrome not only has a major effect on quality of life but also carries a 
substantial socio-economic burden. Diagnosis is based on the existence of widespread pain 
for at least three months in absence of a disorder that would otherwise explain the pain (21). 
Diagnostic criteria have been published (21), and used for inclusion by the studies described 
below. 
 
The pathophysiologic basis of FM remains a matter of debate (22). There are considerable 
clinical and paraclinical data that suggest central nervous system (CNS) alterations in patients 
with FM (23). More recently, peripheral nervous system (PNS) abnormalities have also been 
described. Inflammatory changes on skin biopsies were initially reported (24), followed by 
IENFD reduction in a proportion of FM patients (25). A PNS role in the pathophysiology of 
FM was suggested in a subgroup of FM patients with a chronic polyneuritis similar to chronic 
inflammatory demyelinating polyneuropathy (CIDP) partially responding to immunoglobulin 
therapy (26). Reduced intra-epidermal nerve fiber density (IENFD) on skin biopsy indicative 
of small fiber involvement was subsequently described in patients with FM compared to 
healthy controls.  Table 2 summarizes studies of SFN in fibromyalgia. The first report on 
nerve fiber density in FM was published in 2013 (27). In this study patients with FM were 
investigated with pain-related evoked potentials, IENFD in skin punch biopsies and 
quantitative sensory testing (QST), and compared to healthy controls and patients with 
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monopolar depression. Patients with FM had impaired small fiber function in QST and pain-
related evoked potentials, as well as significant reductions in dermal unmyelinated nerve 
fibers in skin samples from the lower leg and upper thigh. Abnormality of all three methods 
was not seen in all patients, but every patient at least had one abnormal value. These findings 
pointed to a pathological process involving small nerve fibers in FM. In another study, the 
IENFD in pure FM, FM plus autoimmune disorders and healthy controls were studied (28). 
This analysis showed that almost 26% of pure FM patients and around 44% of FM patients 
with another autoimmune disorder have reduced IENFD, in comparison to controls. In a 
further case-control study of patients with pure FM, mean values for both calf and thigh 
specimens IENFD were significantly lower in patients with FM than in controls. In addition, 
they underwent pinwheel and vibratory testing for hypoesthesia and all had varying degrees 
of stocking distribution diminished perception in the lower extremities (29). An electron 
microscopy study provided further evidence of small fiber pathology in FM showing 
diminished nerve fiber diameter in skin biopsies of FM patients compared with controls (30).  
In another recent study, SFN was reported as identified in patients with FM through sensory 
nerve conduction studies and IENFD measurements but not through pain features and 
intensity (31). The relevance of clinical SFN symptoms was however suggested by findings 
of other authors who described dysautonomia as well as paresthesia as predictors of SFN in 
patients with FM (32). Corneal confocal microscopy (CCM) is another diagnostic tool used 
for SFN in FM (33). It is a novel non-invasive method to detect SFN, exploring the cornea, 
which receives the densest small fiber innervations in the body. Other studies have 
demonstrated alterations of small fiber morphology in patients with FM by CCM (34). Total 
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nerve density, long nerve fibers, and the number of nerves have all been found to be lower in 
patients with FM than in controls (35). Recently, aberrant microRNA (miR-let-7d) has been 
reported in the skin of patients with FM and SFN, correlating with reduced small nerve fiber 
density (36). MicroRNAs have been shown to be involved in a wide range of biological 
processes such as neurogenesis. These findings reinforce the concept that pain in some but 
not all patients with FM has a neuropathic source and point to the role of peripheral 
components. A very recent controlled study of 117 women with FM found reduced IENFD at 
different biopsy sites in 63% versus 10% in women with major depression and chronic 
widespread pain and 18% in healthy controls (p<0.001 versus both) (37). Compared to FM 
patients with normal skin innervation, those with IENFD reduction had higher pain intensity 
(p < 0.05), providing new evidence of a relation between pain severity and SFP in FM.  
   
 
Diagnostically, the latest meta-analysis of reported studies estimated the pooled prevalence of 
SFP at 49% in patients with FM. The prevalence estimate achieved by CCM was greater than 
that with skin biopsy (59% vs. 45%), suggesting the former may be a more sensitive method 
(38). The above findings, taken together, may suggest FM is a heterogenous condition with a 
complex pathobiology and that patients reside along a continuum with at one end a purely 
peripherally-induced and the other end a mainly purely centrally-induced form, and some 
patients in between (39). Of note, non-length-dependent SFN may underlie some 
presentations of FM (40). 
 





Parkinson disease (41) is a progressive neurodegenerative disorder characterized by 
predominant motor signs in conjunction with now well-recognized non-motor features (42). 
Neuropathy was noted in PD from reports on large fiber involvement associated with intra-
jejunal levodopa therapy. Subsequently, different studies demonstrated the higher prevalence 
of peripheral neuropathy in PD patients, indicating both large and small fiber involvement. 
The prevalence of large fiber neuropathy in PD was variable between studies, possibly due to 
methodology and gold standards of diagnosis, but all showed significantly greater prevalence 
in PD patients compared to controls. Several etiologies have been considered for neuropathy 
in PD including antiparkinsonian drugs (L-dopa), inducing or occurring concurrently with 
vitamin B12 or folate deficiency (43, 44). PNS involvement may otherwise constitute an 
intrinsic part of the neurodegenerative pathology of PD.  
 
In favor of this hypothesis, several studies have demonstrated the early presence of alpha-
synuclein deposition in small nerve fibers in skin samples. Table 3 summarizes the published 
literature on the association of SFN with PD. Another recent small study reported 4 patients 
with PD with restless legs syndrome (RLS) as a presenting symptom prior to emerging of 
motor symptoms. Skin biopsy showed reduction of IENFD in both proximal and distal sites 
indicative of non-length dependent SFN in all 4 patients (45). Pain and sensory neuropathic 
symptoms are common non-motor symptom in PD, which may imply small fiber 
This article is protected by copyright. All rights reserved.
 
involvement. In another recent case-control study, patients with idiopathic PD and age-and 
sex-matched controls were screened for pain by King’s Parkinson’s Pain Scale and Michigan 
Neuropathy Screening Instrument. The reported pain prevalence was similar in both groups, 
but peripheral neuropathic pain (allodynia, hyperalgesia, burning pain) was significantly 
more prevalent in PD patients than controls and correlated with duration of disease and years 
on levodopa treatment (46). Importantly, confirmation of a peripheral neuropathic origin of 
the pain manifestations in PD requires a correlation with objective markers of small fiber 
nerve damage. On the other hand, sensory impairment as well as loss of free and 
encapsulated nerve endings has been shown in patients with PD, evident in all examined 
sites, unrelated to age, disease duration or levodopa therapy (47). Another study 
demonstrated in >95% of PD patients, at least one abnormality in IENF, contact heat evoked 
potentials, or thermal thresholds of the foot, suggesting small fiber dysfunction (48). In a 
further analysis, treatment-naïve PD patients were evaluated by electrophysiology, skin 
biopsy and CCM and compared to normal controls.  This study showed no significant 
difference between groups in terms of nerve conduction studies and IENFD, but CCM 
showed significant reduction of corneal nerve fiber density and length in PD patients (49). 
Both skin biopsy and CCM was used in another study. Corneal nerve pathology was 
demonstrated in PD-affected subjects, which had a correlation with autonomic symptoms, 
motor function, and parasympathetic deficit. This study found that IENFD was also reduced 
and correlated with corneal fiber density and motor symptoms (50). Finally, one study 
showed by skin biopsy that in both naïve and L-dopa treated patients, small fiber impairment 
occurs in early stage of disease (51). An important finding in this analysis was the 
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asymmetric loss of IENFD which was greater on the side more severely affected by the extra-
pyramidal syndrome, which may suggest that SFN forms part of the underlying disease 
process in PD. Also, alpha-synuclein deposition has been found to be increased in cutaneous 
sympathetic but not in sensory neurons suggesting this may not underlie the sensory and in 
particular painful symptoms (52). 
The issue of pain remains complex in PD. The neuropathic nature of pain is uncertain in all 
cases and is highlighted by some studies (46). The presence of SFP in PD is illustrated by the 
studies above, although its association with pain of definite neuropathic origin in subjects 




 Other synucleionopathies. 
 
REM sleep behavior disorder (RBD) is a parasomnia characterized by loss of muscle tone 
during REM sleep accompanied by abnormal behaviors often occurring with dreams. RBD 
can be symptomatic of α-synucleinopathies (Parkinson disease, Lewy body dementia, 
multiple system atrophy) (53). Recent data suggest that cutaneous changes could be a 
histopathological window and probably a diagnostic tool for neurodegenerative α-
synucleinopathies (54). Patients with RBD may therefore be expected to demonstrate the 
cutaneous abnormalities of SFN. In keeping with this, impairment of somatosensory function 
with increased thermal detection thresholds has been shown in patients with idiopathic RBD 
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(55). In addition, skin biopsy of RBD patients vs. controls demonstrated a significant 
reduction of IENFD, suggesting early PNS involvement (56). Clinical correlation is yet 
uncertain, but recognition of SFN in this setting appears important in view of the growing 
evidence for this association. 
 
 
Amyotrophic lateral sclerosis (ALS) 
There is growing evidence for sensory system involvement in ALS (57). On the other hand, 
pain is recognized as a prevalent complaint in ALS with various mechanisms including 
neuropathic and can be associated with poorer functional status (58) and longer disease 
duration (59). It is important in this regard to recognize the important and wider and issue of 
pain in ALS, with its numerous origins and mechanisms, often unrelated to SFN (60).  
 
Table 4 summarizes the published studies describing the presence of SFN in ALS. One early 
study on post-mortem tissue found nerve growth factor receptor immunostaining in mixed 
peripheral nerves and in dorsal roots, suggesting ALS was not a pure motor disorder (61). 
Sural nerve biopsies in 17 cases of sporadic ALS showed different degrees of axonal loss in 
about 70% of cases. However, these patients with ALS were clinically atypical due to the 
presence of sensory symptoms (62). This suggests that these patients may have had an 
associated sensory neuropathy of undetermined cause. A further case-control study 
demonstrated sural nerve abnormalities in 91% of ALS patients without co-existing disease 
(63). Large-caliber myelinated fibers were predominantly affected in three-quarters of cases 
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with small-caliber myelinated fibers affected in only about a quarter. Thinly myelinated 
fibers were present in 95% and regenerating clusters in 77% of the biopsies.  
  
An initial study of skin biopsies of sporadic ALS patients showed reduction of IENFD in 
almost 80% of patients vs. 12% of controls as well as a reduction in subepidermal and sweat 
gland innervation (64). Another study using QST and skin biopsy demonstrated that 
peripheral sensory nerve involvement in ALS differs according to mode of onset. Patients 
with spinal-onset but not those with bulbar-onset ALS, had both abnormal thermal-pain 
perceptive thresholds and reductions of IENFD (65). However, this was not confirmed by a 
subsequent larger analysis which showed reduction of IENFD similarly in all ALS subtypes 
(66), with no less than 75% of patients with pure ALS demonstrating reduced IENFD. In 
another recent study, in addition to reduced IENFD, Meissner’s corpuscle density, sweat 
gland nerve fiber density as well as pilomotor nerve fiber density were all also reduced. 
Interestingly also, small fiber symptomatology was greater in ALS patients that were pTDP-
43 positive than in those who were pTDP-43 negative (67). This may raise the issue of 
genetic susceptibility for concurrent small fiber pathology in some forms of ALS, but also of 
PD. We are not aware of reported evidence of SFP in familial ALS.  Small fiber involvement 
has also been observed by CCM in ALS. CCM showed that corneal nerve fiber damage 
significantly correlated with bulbar disability scores, but not with age, disease duration or 
spinal level disability (68).  
 
Ehlers Danlos syndrome  
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Ehlers-Danlos syndrome (EDS) describes different inherited connective tissue disorders with 
joint hypermobility, skin texture abnormalities, and visceral and vascular fragility and 
dysfunction (69). A number of different subtypes are reported. An initial questionnaire-based 
analysis found a likely neuropathic component to pain as described in detail (70), with 
another suggesting the responsibility of compressive and axonal neuropathies in the 
hyperalgesia of EDS (71). One subsequent study revealed high prevalence of neuropathic 
pain and of decreased IENFD on skin biopsy, consistent with SFN, in patients with EDS (72). 
This has however, not been replicated in other cohorts, to our knowledge. 
 
Vaccination and SFN 
Human papillomavirus (HPV) vaccination is reported with more adverse reactions than other 
vaccines (73). Common neurologic complications after HPV vaccination have been complex 
regional pain syndrome, postural orthostatic tachycardia syndrome (POTS), and FM, all 
reported with concurrent small fiber neuropathy. In one report, three out of six cases of POTS 
after HPV vaccination had small fiber neuropathy diagnosed by QST (74). Another report 
also describes 5 cases of SFN confirmed by skin biopsy following vaccination for rabies, 
varicella zoster, or Lyme disease (75). These case reports suggested that acute or subacute 
SFN may occasionally follow immunization by other common vaccines. 
 
 
SFN and inflammatory neuropathies 
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In inflammatory demyelinating polyneuropathies (Guillain-Barré syndrome [GBS]; chronic 
inflammatory demyelinating polyneuropathy [CIDP]), large fibers represent the main target 
of the immunologic attack (76). However, there is some evidence confirming the coexisting 
involvement of small fibers in these disorders (77). Especially in patients with GBS, sensory 
signs and symptoms such as hypoesthesia, neuropathic pain and allodynia, in addition to 
autonomic dysfunction, raise the possibility of frequent small fiber pathology. In one study, 
patients with GBS were assessed by quantifying cold and warm detection and pain thresholds 
and responses to suprathreshold painful thermal and mechanical stimuli (QST). Significant 
impairment of these parameters was shown in GBS patients with neuropathic pain compared 
to those with non-neuropathic pain and without pain. Interestingly, motor and sensory large 
fiber dysfunction were similar between groups (78). The same method showed similar results 
in another cohort of patients with GBS, in addition early small fiber nerve involvement in 
those with slow recovery (79). Skin biopsy demonstrated significantly reduced mean IENFD 
in GBS patients compared to controls in a further study (80) where IENFD was reduced in 
55% of cases. In addition, patients with GBS had significantly elevated thermal thresholds 
compared to controls. Reduced IENFD was associated with respiratory distress and 
dysautonomia, and correlated with disability. In addition, case series of acute-onset pure 
small fiber neuropathy as a variant of GBS have also been described. Six patients with small 
fiber neuropathy preceded by infection and associated with CSF albumin-cytologic 
dissociation were reported, all with favorable outcomes (81). Acute presentation of SFN may 
therefore represent part of the GBS spectrum. 
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Similarly, small fiber involvement in CIDP has been shown in a few studies by QST and skin 
biopsy. An association was found between autonomic symptoms and IENFD reduction (82). 
Small fiber and autonomic functions have also been evaluated by quantitative methods. 
Autonomic symptoms were uncommon, but autonomic deficits as measured by the 
Composite Autonomic Severity Score (CASS) were frequent (47%), though very mild, 
cholinergic and predominant sudomotor. QST showed small fiber abnormalities in 72% of 
patients. There was no association between the presence of small fiber abnormalities (QST) 
and definite autonomic deficits on CASS (83). There are few reports of painful small fiber 
neuropathy in association with anti-MAG antibody (84), although this may be under-
recognized despite the frequent present of pain this disorder (85). Potassium/sodium 
hyperpolarization-activated cyclic nucleotide-gated ion channel 2, which is encoded by the 
HCN2 gene, has been identified as an important regulator of nociceptive pain (86). Voltage-
gated potassium channels (VGKC) work synergistically with these channels to maintain 
nociceptive afferent sensory neural thresholds. One of the recently discovered mechanisms of 
chronic idiopathic pain is small fiber nerve hyperexicitability, by involvement of these 
channels. Mutations of sodium channels (Nav1.7 & Nav1.8) have been described in affected 
individuals of chronic pain with or without small fiber loss (87), but this nerve 
hyperexicitability may also result from autoimmunity against VGKC. Anti-VGKC antibodies 
were first described in Isaac’s and Morvan’s syndromes. Contactin Associated Protein 2 
(CASPR2) is a subunit of the VGKC complex and is included in the group of extracellular 
antigens. In a large study of 54,853 patients with diverse neurologic presentations, pain was 
significantly associated with CASPR2-IgG-positivity, the antibody being detected in 16% of 
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patients with pain and in only 7% without pain (p=0.014). Pain was of subacute onset, but 
with a chronic course, both neuropathic and nociceptive, regional, or diffuse. Some patients 
had been diagnosed with FM (6%) or as having psychogenic  pain(13%). Electrophysiologic 
studies in affected individuals were normal, suggestive of small fiber dysfunction, but skin 
biopsy was not  performed (88). Finally, anti-GQ1b antibodies were recently described in a 




























A number of different conditions, not primarily considered as having an accompanying 
neuropathic component, have recently been described with SFN.  
 
In the evaluation of neuropathy in neurologic practice, SFN is frequently suspected following 
clinical evaluation and a normal electrophysiological examination. The modalities of further 
targeted testing in this case scenario are now better established, with the increasing 
availability of skin biopsy in addition to QST, and with the advent of CCM. The findings of 
this review highlight the importance of considering the wider clinical setting, in addition to 
traditionally well-known etiologies of SFN such as diabetes, IGT or vitamin deficiencies. 
Although the frequencies of the different associations currently remain unknown, thorough 
clinical assessment through history-taking and examination, appears warranted given the 
possible associations or underlying extra-pyramidal, anterior horn cell or rheumatologic 
disease, all of which may equally require specialist input. Similarly, appropriate attention is 
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required in presentations of neuropathic pain in subjects with known FM, PD, ALS, RBD or 
EDS.  The literature reviewed suggests that it is important to keep in mind that SFN may be a 
part of a more complex disorder, rather than necessarily being considered a separate entity 
with only a limited number of causes. As discussed above with regard to PD, the issue of pain 
is frequently complex and requires careful consideration and separation of neuropathic from 
non-neuropathic origins. 
 
In practice, the reported associations also have a number of implications. Focusing diagnostic 
and therapeutic management efforts solely on small fiber symptoms may be insufficient and 
directing the clinical assessment in search of features of possible concurrent disorders 
warrants increased emphasis. This may benefit from extended history-taking and more 
exhaustive examination with adequate consideration of potentially neglected non-
neurological elements, such as joint pain or hypermobility. Similarly, given higher prevalence 
rates of the other possible concurrent disorders, therefore making them more likely to be 
encountered in general practice, greater attention to symptoms associated with SFN is 
warranted in patients with established other diagnoses.  In such patients, appropriate 
additional investigations as well as consideration of treatment may be essential despite the 
known, main diagnosis. The examples of PD and ALS are particularly striking, as in both 
disorders, additional neuropathic pain represents an obvious cause of further quality of life 
impairment, which may be amenable to treatment. 
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In conclusion, SFN is now recognized as being a more complex disorder, occurring in 
previously unrecognized settings, associated with other unexpected disorders, but of 
relatively straightforward diagnosis if a high index of suspicion is maintained. SFN is, most 
importantly, potentially treatable. Greater awareness of this growing literature appears 











Table 1. Reported unexpected diseases associated with small fiber neuropathy. 
 
Neurological Non-neurological 
Amyotrophic lateral sclerosis Fibromyalgia 
Parkinson’s disease Ehlers Danlos Syndrome 
Rapid eye movement sleep behavior disorders Obstructive Sleep Apnea Syndrome 
Pure Autonomic Failure Vaccination 
Dementia with Lewy Bodies Fragile X Syndrome 
This article is protected by copyright. All rights reserved.
 
Inflammatory Large Fiber Neuropathies Leprosy 
Acute Intermittent Porphyria Chagas Disease 




















Table 2. Studies reporting SFN in Fibromyalgia. 
Study case/control Method Results 
Doppler K.(30) 32/24 Skin biopsy ↓mean axon diameter 
Giannoccaro MP.(25) 20/0 Skin biopsy ↓IENFD1 (6 case) 
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Erkan Turan K. (35) 34/42 CCM2 ↑Ocular surface alterations 
↓Nerve density 
Manuel Ramírez (34) 17/17 CCM ↓Mean stromal nerve thickness 
↓Mean sub-basal plexus nerve density 
Michalis L. Kosmidis(28) 46/34 Skin biopsy ↓IENFD in 15/46 
Xavier J. Caro(29) 41/47 Skin biopsy ↓Mean IENFD 
Üçeyler N.(27) 
 





2.impaired small fiber function 
3.↑N1 latencies upon stimulation and    
↓amplitudes of pain-related evoked potentials 
Oudejans L.(33) 39/0 CCM 51% small fiber pathology 
Oaklander AL.(40) 
 
27/30 1.Skin biopsy 
2. MNSI4 
3. UENS5 
1. ↓IENFD in 41% vs. 3% 
2.↑Mean MNSI 
3. ↑Mean UENS 
 
IENFD: Intraepidermal nerve fiber density, CCM: corneal confocal microscopy, QST: Quantitative 









Table 3. Studies reporting SFN in Parkinson Disease. 
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Study  Case/control Method  Results  
Podgorny PJ.(49) 26/22 1.Skin biopsy 
2.UENS 
3.CCM 
1. No difference in IENFD 
2.Abnormal UENS in 
38%/23% 
3.↓Mean CNFL 
Giannoccaro MP. (90) 22/11 1.(123) I-MIBG myocardial 
scintigraphy 
2. Skin biopsy 
Abnormal both in 91% 
Nolano M.(47) 18/30 1. Skin biopsy 
2.QST 
1.↓Mean IENFD 




Nolano M. (51) 85 1. Skin biopsy 
2.QST 
1.↓ Mean IENFD, higher in 
the more affected side 
2. ↑ tactile and thermal 
thresholds, impairment of 
mechanical pain perception, 
and ↓sweat output 
Kass-Iliyya L. (50) 26/26 1. Skin biopsy 
2.CCM 
1.↓ IENFD 
2.↓ CNFD, ↑CNBD, 
↑CNFL 
Dabby R. (91) 22/19 Skin biopsy ↓ blood vessels, sweat 
glands, and erector pili 
muscles autonomic 
innervation 
Nolano M. (92) 28 1.SFN-SIQ and SCOPA-
AUT  
2.neurographic study 
-changes in sensory and 
autonomic function 
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3.QST; SSR; DST 
4. skin biopsy 
and IENF density correlate 
disease duration, severity, 
stage, 
-side-to-side asymmetry 
CNFL: Corneal nerve fiber length, CNFD: Corneal nerve fiber density, CNBD: corneal nerve branch 
density, SFN-SIQ: small-fiber neuropathy- Symptoms Inventory Questionnaire, SCOPA-AUT: Scales 


































Table 4. Studies reporting SFN in ALS 
 
Study  Case/control Method Results 
Truini A.(65) 24/0 1.QST 
2. Skin biopsy 
1. Both normal in 
bulbar-onset 
2. Both abnormal in 
spinal-onset 
 
Ren Y.(67) 18/18 Skin biopsy 
 
↓ Mean IENFD, MCD, 
SGNFD, PNFD 




3. Clinical evaluation 
1.↓Large fiber in 73%, 
↓small fiber in 23% 
2.↓Sural SNAP in 27% 
3. Sensory symptoms or 
signs in 32% 
Weis J. (64) 28/17 Skin biopsy ↓ IENFD in 79% vs 12% 
Dalla Bella E. (66) 57 Skin biopsy ↓ IENFD in 75.4% of 
ALS and 50% of 
FOSMN patients 
Ferrari G. (68) 8/7 CCM ↓ Mean CNFD 
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Sassone J. (93) ALS mouse model 
SOD1G93A 
Skin biopsy ↓Mean IENFD 
 
MCD: Meissner's corpuscle density, SGNFD: sweat gland nerve fiber density, PNFD: pilomotor nerve fiber 





ALS: amyotrophic lateral sclerosis; CIDP: chronic inflammatory demyelinating polyneuropathy; CCM: 
corneal confocal microscopy; EDS: Ehlers-Danlos syndrome; FM: fibromyalgia; GBS: Guillain-Barré 
syndrome; HPV: human papillomavirus; IENFD: intraepidermal nerve fiber density; IGT: impaired 
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